The estimated Net Worth of Adam D. George is at least $708 Thousand dollars as of 21 January 2021. Mr. George owns over 39,288 units of GW Pharmaceuticals stock worth over $1,729 and over the last 6 years he sold GWPH stock worth over $0. In addition, he makes $705,864 as Managing Director - U.K. and Company Secretary at GW Pharmaceuticals.
Sign up
Mr. George GWPH stock SEC Form 4 insiders trading
Adam has made over 5 trades of the GW Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 39,288 units of GWPH stock worth $377,558 on 21 January 2021.
The largest trade he's ever made was exercising 675,744 units of GW Pharmaceuticals stock on 13 January 2021 worth over $250,025. On average, Adam trades about 153,259 units every 113 days since 2018. As of 21 January 2021 he still owns at least 24,700 units of GW Pharmaceuticals stock.
You can see the complete history of Mr. George stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Adam George biography
Adam David George serves as Managing Director - U.K., Company Secretary of the Company. Adam George joined the Company in 2007 and was Group Financial Controller until June 2012, at which time he was our Chief Financial Officer until March 2017. On March 6, 2017, Mr. George was appointed as Managing Director, U.K., a newly-created executive role with broad leadership responsibilities for our U.K. operations. Mr. George also acts as Company Secretary, a role he has held since he first joined the Company. Prior to joining the Company, Mr. George occupied several senior finance roles within both listed and privately-owned high growth businesses. He is currently a non-executive director of Nucana plc, a clinical-stage biopharmaceutical company.
What is the salary of Adam George?
As the Managing Director - U.K. and Company Secretary of GW Pharmaceuticals, the total compensation of Adam George at GW Pharmaceuticals is $705,864. There are 6 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of $7,864,300.
How old is Adam George?
Adam George is 50, he's been the Managing Director - U.K. and Company Secretary of GW Pharmaceuticals since 2017. There are 11 older and 2 younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
What's Adam George's mailing address?
Adam's mailing address filed with the SEC is SOVEREIGN HOUSE, VISION PARK, HISTON, , CAMBRIDGE, X0, CB24 9BZ.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble, and Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
What does GW Pharmaceuticals's logo look like?
Complete history of Mr. George stock trades at GW Pharmaceuticals
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America